PML, located at chromosome 15, was originally identified to be involved in reversible chromosomal translocation with Retinoic Acid Receptor alpha (RARα) at chromosome 17, forming fusion oncoprotein PML-RARα which, acting as a dominant negative form of PML, abrogates PML’s tumor suppressive functions [152]. Here, RARA is linked to neoplasm.